Format

Send to

Choose Destination
Ann N Y Acad Sci. 2011 Jun;1228:81-92. doi: 10.1111/j.1749-6632.2011.06015.x.

PET/CT in diagnosis of dementia.

Author information

1
Department of Clinical Pathophysiology, Nuclear Medicine Unit, University of Florence, Florence, Italy. valentina.berti@unifi.it

Abstract

Clinical use of positron emission tomography (PET) is now well established in neurodegenerative disorders, especially in the diagnosis of dementia. Measurement of cerebral glucose metabolism is of significant value, and it facilitates early diagnosis, appropriate differential diagnosis, and the evaluation of drug treatment in patients with dementia. In addition, tracers offer new perspectives for studying the neuropathology of underlying dementia, such as the accumulation of amyloid proteins, tau-proteins, or the presence of neuroinflammation. Finally, PET tracer studies of different neurotransmitter systems in dementia may not only increase the understanding of pathophysiologic mechanisms of the different disorders, but also improve diagnostic accuracy. In conclusion, PET imaging with different tracers offers reliable biomarkers in dementia, which can assist clinicians in the diagnosis of different dementing disorders, especially in the situation of overlapping phenotypes.

PMID:
21718326
PMCID:
PMC3692287
DOI:
10.1111/j.1749-6632.2011.06015.x
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center